# IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

> clinical trial · VERIFIED · 2026-07-16

Status: ACTIVE_NOT_RECRUITING · Sponsor: University of California, Davis · Condition: High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

- Company: University of California, Davis
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT05843448

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.